参考文献/References:
[1] Thygesen K,Alpert JS,Jaffe AS,et al. Fourth niversal definition of myocardial infarction (2018)[J]. Circulation,2018,138(20):e618-e651.
[2] Merlo AC,Bona RD,Ameri P,et al. Type 2 myocardial infarction:a diagnostic and therapeutic challenge in contemporary cardiology[J]. Intern Emerg Med,2022,17(2):317-324.
[3] Byrne RA,Rossello X,Coughlan JJ,et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J,2023,44(38):3720-3826.
[4] DeFilippis AP,Hall ME. Impact of new ICD codes on acute mi characteristics and outcomes:what you call it matters[J]. J Am Coll Cardiol,2021, 78(12):1254-1256.
[5] Sandoval Y. Type 2 myocardial infarction:the need to operationalise diagnostic criteria and shift towards clinical trials[J]. Heart,2023,109(20):1504-1505.
[6] Sandoval Y,Smith SW,Sexter A,et al. Use of objective evidence of myocardial ischemia to facilitate the diagnostic and prognostic distinction between type 2 myocardial infarction and myocardial injury[J]. Eur Heart J Acute Cardiovasc Care,2020,9(1):62-69.
[7] Knott JD,De Michieli L,Ola O,et al. Diagnosis and prognosis of type 2 myocardial infarction using objective evidence of acute myocardial ischemia: a validation study[J]. Am J Med,2023,136(7):687-693.e2.
[8] Bularga A, Hung J,Daghem M,et al. Coronary artery and cardiac disease in patients with type 2 myocardial infarction:a prospective cohort study[J]. Circulation,2022,145(16):1188-1200.
[9] Meah MN,Bularga A,Tzolos E,et al. Distinguishing type 1 from type 2 myocardial infarction by using CT coronary angiography[J]. Radiol Cardiothorac Imaging,2022,4(5):e220081.
[10] Wereski R,Kimenai DM,Bularga A,et al. Risk factors for type 1 and type 2 myocardial infarction[J]. Eur Heart J,2022,43(2):127-135.
[11] White HD,Steg PG,Szarek M,et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial[J]. Eur Heart J,2019,40(33):2801-2809.
[12] Chapman AR,Adamson PD,Shah ASV,et al. High-sensitivity cardiac troponin and the universal definition of myocardial infarction[J]. Circulation,2020,141(3):161-171.
[13] Pandey AK,Duong T,Swiatkiewicz I,et al. A comparison of biomarker rise in type 1 and type 2 myocardial infarction[J]. Am J Med,2020,133(10):1203-1208.
[14] Nowak RM,Jacobsen G,Christenson RH,et al. Differentiating type 1 and 2 acute myocardial infarctions using the N-terminal pro B-type natriuretic peptide/cardiac troponin T ratio[J]. Am J Emerg Med,2018,36(10): 1849-1854.
[15] Putot A,Jeanmichel M,Chagué F,et al. Type 1 or type 2 myocardial infarction in patients with a history of coronary artery disease:data from the emergency department[J]. J Clin Med,2019,8(12).2100.
[16] Bormann J,Psyrakis DA,von Jeinsen B,et al. Myeloid-related protein 8/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction[J]. Int J Cardiol,2020,304:144-147.
[17] Horiuchi Y,Wettersten N,Patel MP, et al. Biomarkers enhance discrimination and prognosis of type 2 myocardial infarction[J]. Circulation,2020, 142(16):1532-1544.
[18] Nestelberger T,Boeddinghaus J,Lopez-Ayala P,et al. Cardiovascular biomarkers in the early discrimination of type 2 myocardial infarction[J]. JAMA Cardiol,2021,6(7):771-780.
[19] Neumann JT,Weimann J,S?rensen NA,et al. A biomarker model to distinguish types of myocardial infarction and injury[J]. J Am Coll Cardiol,2021,78(8):781-790.
[20] ?erpytis R,Lizaitis M,Majauskien? E,et al. Type?2 myocardial infarction and long-term mortality risk factors: a retrospective cohort study[J]. Adv Ther,2023,40(5):2471-2480.
[21] Raphael CE,Roger VL,Sandoval Y,et al. Incidence,trends,and outcomes of type 2 myocardial infarction in a community cohort[J]. Circulation,2020,141(6):454-463.
[22] Raphael CE,Roger VL,Sandoval Y,et al. Causes of death after type 2 myocardial infarction and myocardial injury[J]. J Am Coll Cardiol,2021,78(4):415-416.
[23] Nestelberger T,Boeddinghaus J,Badertscher P,et al. Effect of definition on incidence and prognosis of type 2 myocardial infarction[J]. J Am Coll Cardiol,2017,70(13):1558-1568.
[24] de Lemos JA,Newby LK,Mills NL. A proposal for modest revision of the definition of type 1 and type 2 myocardial infarction[J]. Circulation,2019,140(22):1773-1775.
[25] Schoepfer H,Nestelberger T,Boeddinghaus J,et al. Effect of a proposed modification of the type 1 and type 2 myocardial infarction definition on incidence and prognosis[J]. Circulation,2020,142(21):2083-2085.
[26] Taggart C,Monterrubio-Gómez K,Roos A,et al. Improving risk stratification for patients with type 2 myocardial infarction[J]. J Am Coll Cardiol,2023,81(2):156-168.
[27] Cediel G,Sandoval Y,Sexter A,et al. Risk estimation in type 2 myocardial infarction and myocardial injury: the TARRACO risk score[J]. Am J Med,2019,132(2):217-226.
[28] Murphy SP,McCarthy CP,Cohen JA,et al. Application of the GRACE,TIMI,and TARRACO risk scores in type 2 myocardial infarction[J]. J Am Coll Cardiol,2020,75(3):344-345.
[29] Hung J,Roos A,Kadesj? E,et al. Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction[J]. Eur Heart J,2021,42(26):2552-2561.
[30] 王星雨,胡思琪,李武林,等. ICU机械通气患者发生2型心肌梗死的影响因素研究[J]. 实用心脑肺血管病杂志,2022,30(2):39-43.
[31] 李一德,佘颖芳,吴先明,等. N端B型钠尿肽前体和肌钙蛋白I比值鉴别1型和2型心肌梗死的诊断价值研究[J]. 中国急救复苏与灾害医学杂志,2019,14(12):1206-1208,1218.
相似文献/References:
[1]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(6):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[2]崔小豪 杨志明.和肽素在急性心肌梗死中的研究进展[J].心血管病学进展,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
CUI Xiaohao,YANG Zhiming.Copeptin in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(6):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
[3]李凤鹏 张军.2型心肌梗死和心肌损伤的研究进展[J].心血管病学进展,2019,(9):1275.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.023]
LI Fengpeng,ZHANG Jun.Type 2 Myocardial Infarction and Myocardial Injury[J].Advances in Cardiovascular Diseases,2019,(6):1275.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.023]
[4]张艺文 汪汉 秦莉 杨晓倩 童兰 蔡琳.狼疮患者冠心病的诊断、风险评估和治疗[J].心血管病学进展,2020,(5):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
ZHANG Yiwen,WANG Han,QIN Li,et al.Diagnosis, Risk Evaluation and Therapy of Coronary Heart Disease in Lupus Patients[J].Advances in Cardiovascular Diseases,2020,(6):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
[5]刘晓霞 吴宝全.外周血miR-26a-5p水平变化与高血压性左心室肥厚的关系分析[J].心血管病学进展,2020,(5):556.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.027]
LIU Xiaoxia,WU Baoquan.Relationship Between Changes of Peripheral Blood miR-26a-5p Levels and Hypertensive Left Ventricular Hypertrophy[J].Advances in Cardiovascular Diseases,2020,(6):556.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.027]
[6]袁佳栎 王群山.人工智能在心律失常诊断中的前景与挑战[J].心血管病学进展,2020,(10):999.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.001]
YUAN JialiWANG Qunshan.Prospects and Challenges of Arrhythmia Diagnosis by Artificial Intelligence[J].Advances in Cardiovascular Diseases,2020,(6):999.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.001]
[7]栾梦迪,吴立荣.院内发生的心肌梗死研究现况[J].心血管病学进展,2020,(10):1061.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.015]
LUAN Mengdi,WU Lirong.Research Status of AMI occurring in Hospitalized Patients[J].Advances in Cardiovascular Diseases,2020,(6):1061.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.015]
[8]王前程 刘伟涛 周忠江.提高对甲状腺素转运蛋白淀粉样变性心肌病诊治的认识[J].心血管病学进展,2021,(3):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
WANG Qiancheng,LIU Weitao,ZHOU Zhongjiang.To Improve the Recognition of Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(6):228.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.009]
[9]韩雅洁 范小倩 巩彩霞 赵子龙 乔成栋.致心律失常性左室心肌病的研究进展[J].心血管病学进展,2021,(4):342.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.013]
HAN Yajie,FAN Xiaoqian,GONG Caixia,et al.Arrhythmogenic Left Ventricular Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(6):342.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.013]
[10]余幸娟 王琦光.胎儿先天性心血管病诊疗现状与前景[J].心血管病学进展,2021,(6):547.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.017]
YU XingjuanWANG Qiguang.Current Situation and Prospect of Diagnosis and Treatment of Fetal Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2021,(6):547.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.017]